{"organizations": [], "uuid": "92ebe904620188fa3e9958328f12e47b690b16a5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180426.html", "section_title": "Archive News &amp; Video for Thursday, 26 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/abbvie-results/abbvie-beats-quarterly-revenue-estimates-raises-earnings-forecast-idUSL3N1S34VK", "country": "US", "domain_rank": 408, "title": "AbbVie beats quarterly revenue estimates, raises earnings forecast", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-26T19:50:00.000+03:00", "replies_count": 0, "uuid": "92ebe904620188fa3e9958328f12e47b690b16a5"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/abbvie-results/abbvie-beats-quarterly-revenue-estimates-raises-earnings-forecast-idUSL3N1S34VK", "ord_in_thread": 0, "title": "AbbVie beats quarterly revenue estimates, raises earnings forecast", "locations": [], "entities": {"persons": [{"name": "imbruvica", "sentiment": "none"}, {"name": "mrinalini krothapalli", "sentiment": "none"}, {"name": "tamara mathias", "sentiment": "none"}, {"name": "abbvie", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}, {"name": "humira", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "abbvie inc", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 26 (Reuters) - AbbVie Inc’s first-quarter revenue beat analysts’ estimates on Thursday on higher sales of its rheumatoid arthritis drug Humira and cancer treatment Imbruvica, while raising full-year earnings forecast.\nThe company’s net revenue rose 21.4 percent to $7.93 billion, ahead of average estimate of $7.59 billion, according to Thomson Reuters I/B/E/S.\nSales of Humira, which account for nearly two-thirds of the company’s total revenue, rose to $4.71 billion, beating estimates of $4.64 billion.\nImbruvica raked in $762 million in sales, above expectations of $755.77 million.\nThe drugmaker raised its 2018 adjusted earnings per share expectation to between $7.66 and $7.76, from between $7.33 and $7.43 previously forecast.\nThe forecast accounts for an effective tax rate approaching 9 percent this year, AbbVie said.\nNet earnings rose to $2.78 billion, or $1.74 per share, in the three months ended March 31, from $1.71 billion, or $1.06 per share, a year earlier.\nExcluding items, AbbVie earned $1.87 per share. (Reporting by Tamara Mathias and Mrinalini Krothapalli in Bengaluru; Editing by Shounak Dasgupta)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-26T19:50:00.000+03:00", "crawled": "2018-04-27T16:58:31.009+03:00", "highlightTitle": ""}